AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?
Key PointsAbbVie is successfully navigating a critical transition period as newer immunology drugs offset revenue declines from legacy products.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.